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Sexual dysfunction is common in patients suf-
fering from chronic renal failure. In one study of 519
patients, 48% of males and 26% of females encoun-
tered this problem [1]. Usually, females have loss of
libido, anovulatory vaginal bleeding or amenorrhea,
and males have loss of libido and impotence. During
maintenance dialysis therapy, only 8% of males and
6% of females experience improvement in sexual
function. As a result, pregnancy occurs in only
about I of 200 women of childbearing age having
dialysis therapy [2]. Very few of these pregnancies
result in live births at term [2—5]. Many patients ex-
perience improvement of sexual function following
successful renal transplantation, however, and fer-
tility increases. Thus, patients have the opportunity
to become parents if they so desire [6, 7], and about
1 of every 50 women of childbearing age having a
functioning renal transplant becomes pregnant [2].
Average survival figures of large numbers of pa-
tients from all over the world indicate that between
61 and 78% of recipients of kidneys from related liv-
ing donors are alive 5 years after transplantation,
and with cadaver kidneys the figure is 42 to 51% [8].
Functional survival of the kidney graft at 5 years is
45 to 66% in recipients of living donor kidneys, and
29 to 35% in recipients of cadaver organs [8]. Cur-
rently, between 4,000 and 4,500 patients per year
are undergoing renal transplantation in this country.
As the number of long-term survivors is growing, it
is important that physicians should be acquainted
with the problems surrounding parenthood in these
patients [6, 7]. This article will describe our experi-
ence in dealing with such individuals and their off-
spring.
Clinical material. From March of 1962 till Janu-
ary of 1979, 697 patients underwent 910 renal trans-
plantations at the University of Colorado Health
Sciences Center and the Denver Veterans Adminis-
tration Medical Center. The number of transplants
per patient ranged from 1 to 7. In the great majority
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of patients, renal failure was caused by chronic gb-
merulonephritis or pyelonephritis. Other causes
were diabetes mellitus, polycystic kidney disease,
familial nephritis, Goodposture's syndrome, medul-
lary cystic disease, cystinosis, obstructive urop-
athy, hemolytic uremic syndrome, lupus nephritis,
oxalosis, ethylene glycol nephropathy, and trauma
[9].
The renal homograft was usually placed extra-
peritoneally in the iliac fossa [10]. Most commonly,
the renal blood supply was provided by an end-to-
end anastomosis of the recipient's hypogastric ar-
tery to the renal artery, and an end-to-side anasto-
mosis between the renal and external iliac veins.
Urinary outflow was most frequently provided by a
ureteroneocystostomy, but ureteroureterostomy
was used in a few patients [10]. All patients, except
4 identical twin recipients, received immuno-
suppression with azathioprine (Imuran) and adrenal
corticosteroids (prednisone or methyipredniso-
lone). Other immunosuppressive measures used in
some patients included splenectomy, thymectomy,
thoracic duct drainage, actinomycin C, cyclo-
phosphamide, or local radiotherapy to the renal
homograft [9—11].
Parenthood was theoretically possible in 376 of
the 697 patients. Of the 321 patients excluded, 239
had died at intervals ranging from days to years af-
ter transplantation, 37 could not be contacted, 16
were in the pediatric age group, 14 were post-
menopausal women, and 15 patients or their
spouses had undergone sterilization procedures
(tubal ligation, hysterectomy, or vasectomy). in the
group of 376 patients capable of having children, 50
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male and 40 female recipients did achieve parent-
hood. Two additional female patients, who received
their transplant at other centers are included in this
series, as their management during and after a preg-
nancy was conducted at our institution. Five of the
female patients, who had 3 live births and 2 abor-
tions, will not be considered further, as we have in-
adequate data concerning their pregnancies. For the
same reason, we shall not discuss 2 female liver
transplant recipients who had a total of 3 preg-
nancies. Among the patients that we shall consider
in detail, there was a total of 123 pregnancies. These
included 10 abortions (7 therapeutic and 3 spontane-
ous), 1 ectopic pregnancy, 1 stillbirth, and 104 live
births (including 1 set of twins). Three female recip-
ients and the wives of 5 male patients are currently
pregnant (Table 1).
Parenthood in male patients
Two factors have served as a deterrent to parent-
hood in a number of male renal transplant recipi-
ents. In the early years of transplantation, it was
routine practice in many medical centers to divide
the spermatic cord when obtaining exposure in the
iliac fossa for insertion of the kidney homograft.
When this was done bilaterally, as in patients who
needed two or more transplants, the patient was left
sterile. This was not a problem in the early years of
transplantation when patient survival was a few
weeks or months. As long-term survivals were at-
tained and parenthood became a possibility, we rec-
ommended that every effort be made to preserve
the spermatic cord [12]. This procedure is now
widely practiced.
Although iatrogenically induced sterility has been
eliminated almost completely, impotence remains a
problem. Sexual dysfunction occurs in 48% of men
suffering from chronic renal failure [1]. In many cas-
es, this improves after restoration of satisfactory
renal function by transplantation, but it may persist
or even develop de novo. In several series, impo-
tence was present in 22 to 43% of male kidney trans-
plant recipients [1, 13-14] (Tkach and Penn, unpub-
lished observations).
Despite these problems, 50 males in the present
series have been responsible for 67 pregnancies up
to the present time.
Parenthood in female patients
Menstruation and contraception following renal
transplantation. Prior to transplantation, the female
patients were either amenorrheic or had infrequent
episodes of vaginal bleeding, which occurred at in-
tervals ranging from 3 to 6 months. On the average,
menstruation reappeared within 6 months after
transplantation.
With the uncertainties about life expectancy,
continuing renal function, and the prospects of hav-
ing normal offspring following renal transplantation,
the patients were counseled about family planning.
They were advised to practice contraception for at
least 18 months postoperatively. In a few instances,
however, pregnancies did occur at an early period
after transplantation in individuals who were under
the mistaken impression that they were incapable of
having children and, therefore, did not take any
contraceptive precautions.
Pregnancy following renal transplantation. Fe-
male patients are instructed to consult their obste-
tricians as soon as pregnancy is suspected. Such pa-
tients should be followed in a high-risk obstetric
clinic, in conjunction with a member of the trans-
plant team or a nephrologist, at biweekly intervals
until the 36th week of gestation and then weekly un-
til the onset of labor. The patient's blood pressure
and weight should be measured. Standard renal
function tests, including determinations of blood
urea nitrogen levels, serum creatinine levels, and
creatinine clearance are performed frequently. The
urine is analyzed for specific gravity, 24-hour pro-
tein content, glucose, and electrolyte levels. In ad-
dition, microscopic examinations are performed,
and cultures are obtained. Usually, no significant
changes in immunosuppressive therapy are re-
quired during the pregnancies.
In the 37 female patients, the original renal dis-
ease was chronic glomerulonephritis in 25, chronic
pyelonephritis in 5, polycystic disease in 1, Henoch
Table 1. Parenthood in kidney homograft recipients
No. of
parents
No. of
pregnancies
No. of
abortions
No. of ectopic
pregnancies
No.of
current
pregnancies
No.of
live
births
No. of
stillbirths
Fathers 50
Mothers37
67
56
2
8
0
1
5
3
60
44
0
1
Includes 1 set of twins
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Schonlein disease in 1, familial nephritis in 1, inter-
stitial nephritis in 1, left renal aplasia and right
chronic phylonephritis in 2, and undiagnosed renal
failure in 1.
Five patients had two to six transplants each be-
fore becoming pregnant (Table 2). Twenty-nine pa-
tients received kidneys from related living donors,
including one from an identical twin. Twelve recipi-
ents were given kidneys from cadaver donors, in-
cluding one from a mother who had died (Table 2).
Data concerning the 56 pregnancies that occurred
in these 37 women are summarized in Tables ito 3.
Twenty-three patients each had single pregnancies,
10 had two, 3 had three, and I had four pregnancies.
The onset of pregnancy ranged from 5 to 159'/2
months following transplantation, with a mean of 50
months. The patient's age at the onset of pregnancy
ranged from 19 to 38 years, with a mean of 24 years.
Three women are currently pregnant. One patient
had an ectopic pregnancy, and there were eight
abortions (Table 2). One of these was spontaneous
(patient i4a). Of the seven therapeutic abortions,
most were performed at the patients' request be-
cause they did not wish to become parents. In addi-
tion, in 5 of these patients (patients 6, 9, 16, 19, and
36b), impaired renal function and/or hypertension
helped in making the decision in favor of a thera-
peutic abortion, and in 2 of the patients emotional
instability was also present (patients 16 and 19).
Renal and vascular studies during and after preg-
nancy. The results of renal function studies, the pa-
tients' highest blood pressures before, during, and
after pregnancy, and the length of followup are pre-
sented in Table 3. Prior to pregnancy, renal function
studies varied from essentially normal to markedly
impaired. In 21 pregnancies (patients 2a, 6, 9, 12a,
b, and c, 15a, b, and c, 16, 19, 21, 25a and b, 26, 28,
29, 30, 33, 36a and b), the patients had evidence of
preexisting hypertension and/or renal impairment.
Five of these pregnancies (patients 6, 9, 16, 19, and
36b) ended in therapeutic abortions, as described
above. In 10 of the gestations associated with prior
renal impairment (patients 12a and c, 15c, 21, 25a
and b, 26, 28, 33, and 36a), there was a superim-
posed preeclampsia (determined clinically; no renal
biopsies were performed) on preexisting hyper-
tension, and one of these ended in premature labor
at 29 weeks (case 21). In 2 patients (patients 28 and
33), renal function deteriorated in the postpartum
period. In another patient (15c) renal function re-
mained stable during the first 5 months of her third
pregnancy, but deteriorated during the last few
months and continued to deteriorate postpartum.
She required a second renal transplant from a ca-
daver donor 5 months after delivery, but died of over-
whelming sepsis 4 months later. One patient (36a)
developed albuminuria but no other clinical mani-
festations of toxemia during pregnancy, and revert-
ed to normal after delivery. The remaining 6 preg-
nancies in this group with preexisting impaired
renal function progressed without any further
aggravation of their impaired function or hyper-
tension (2a, 12b, iSa and b, 29, and 30).
Preeclampsia occurred in an additional 5 gesta-
tions (la, 13, 20a and b, and 3la), and of these 3
delivered prematurely. Thus, the overall incidence
of toxemia was 27%. In the remaining 30 gestations,
1 patient (32) demonstrated evidence of deteriora-
tion of renal function during pregnancy and in the
postpartum period. Thus, in 4 of the 56 pregnancies
(7%), there was deterioration of renal function that
could be attributed to the pregnancy, 3 in patients
with impaired function before conception, and 1
with normal function prior to pregnancy.
The length of followup has ranged from 4 to 141
months (mean, 59 months) with the exception of 3
patients who are still pregnant. Four patients died
(Il, 15, 16, and 17) following termination of preg-
nancy. In two instances (11 and 16) the patients re-
fused to continue with their immunosuppressive
medications, and death resulted from homograft re-
jection and uremia 50 and 30 months, respectively,
following termination of their pregnancies. The oth-
er 2 patients (15 and 17) died of overwhelming sep-
sis 9 months after a third pregnancy and 82 months
after a second pregnancy, respectively.
Conduct of labor and delivery. Theoretically, the
presence of the transplanted kidney could interfere
with the descent of the presenting fetal part. This,
however, has not been our experience because the
kidney is actually located in the false pelvis. Vagi-
nal delivery has been possible in all except 9 preg-
nancies (4b, 11, 20a and b, 27, 28, 31a, 32, and36a).
The indications for Cesarean section were avascu-
lar necrosis of both hips with impaired abduction
(11), fetal distress (20a, 27, and 36a), repeat section
(20b), cephalopelvic disproportion (4b, 31a and 32),
and an epidural anesthetic complication (28).
Because of the stress of labor, the patients re-
ceived supplemental corticosteroid therapy with
100 mg of hydrocortisone given i.v. every 8 hours
for 24 hours, commencing with the onset of partu-
rition. As immunosuppressed patients are prone to
infection, we wish to reemphasize the importance
of aseptic technique during examination and deliv-
ery. Because of this risk, labor is induced with
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Table 2. Female patients who became pregnant alter renal transplantation
la 23
Imuran Prednisone
Onset of dose dose Duration
Age at pregnancy alter during during of
pregnancy Renal transplantationa pregnancy pregnancy pregnancy
Patient no. yr donor months mg/day mg/day weeks
41(I) Cadaver 54 37.5 10
(2) Cadaver (mother)
lb 26 73 37.5 10 39
2a 19 Sister 5 75 20 33
2b 20 15 75 20 33
3 27 Brother 52 75 Oto 15 38
4a 23 Sister 83 37.5 StolO 13.5
4b 28 143 37.5 StolO 41
5 24 Father 45 62.5 10 18
6 36 Cadaver 16 75 25 10
7 22 Father 35 75 25 36
8 25 Sister 48 87.5 5 33
9 29 (1) Mother
(2) Cadaver
90 112.5 20 5
10 29 Brother 45 125 15 37
11 22 Mother 87 137.5 10 40
12a 22 Mother 46.5 125to 150 0 41
12b 26 96 125to 150 0 40
12c 30 135 125to 150 0 42
13 25 Sister 22.5 100 lOtol5 32
14a 20 Mother 23 87.5 Oto2O 37
14b 59 87.5 Oto2O 36.5
15a 24 Mother 26.5 75 lOtolS 35
15b 26 45 75 lOto 15 Ruptured ectopic
lSc 27 53.5 — — 36
16 29 Mother 12 87.5 15 8
17a 21 Father 31 87.5 10 39
17b 22 47.5 100 10 40
18a 21 Brother 6 87.5 lOtolS 6
18b 23 19.5 87.5 10 33
18c 24 32 87.5 15 34
18d 25 47.5 87.5 15 40
19 24 Cadaver (x 6) 8.5 125 27.5 12
20a 23 Brother 31 100 10 40
20b 25 49.5 100 10 40
21 23 Mother 28 75 15 29
22 21 Sister 78.5 75 15 36
23 26 Sister 12 125 20 40
24 21 Aunt 43.5 50 15 37
25a 22 Cadaver 12 75 2OtolS 40
25b 26 61 75 15 28.5
26 22 Cadaver 92.5 125 30 16
(Still pregnant)
27 21 (1) Mother
(2) Cadaver
36
28 30 Cadaver 40
29 38 Cadaver 26
(Stillpregnant)
30 31 Mother 36
31a 26 Identical twin 40
31b 27 41
31c 29 37
32 28 (1) Cadaver
(2) Cadaver
40
33 26 Father 36
34a 19 Mother 38
34b 21 30
35 24 Sister 30
(Stillpregnant)
36a 23 Brother 5 50 20 36
36b 24 18 100 20 10
37a 22 Sister 27 100 15 to 20 36
37b 23 41 100 15to20 36
10 50
26
67.5
20
100
75
20
10
22
112
130
159.5
94
6
58
86
27
100
0
0
0
75
75/100
75
75
125
15
0
0
0
15
30/35
10
10
10
a After first transplant in patients who received more than one kidney.
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oxytocin in patients who present with premature
rupture of the membranes.
Sterilization after pregnancy. Because of the
risks associated with further pregnancies, 12 of the
37 female patients elected to have tubal ligations af-
ter one or more pregnancies. In addition, 7 women,
including 2 who had had tubal ligations, underwent
hysterectomies because of cervical or uterine can-
cer (2 patients), atypical cervical smears (2 pa-
tients), uterine prolapse (1 patient), pelvic inflam-
matory disease (1 patient), and for unknown rea-
Sons (1 patient).
Offspring of kidney transplant recipients
Male patients. Of the 60 babies, 58 were normal.
One infant was born with a large myelomenin-
gocele, bilateral dislocated hips, and bilateral tal-
ipes equinovarus [15]. The mother did not receive
any medications during an apparently uncompli-
cated pregnancy; there was, however, a family his-
tory of spina bifida. Another infant with multiple
congenital anomalies, including microcephaly and
polycystic kidneys, died at birth.
Female patients. Of the 56 pregnancies, 43 have
resulted in live births including one set of twins
(25b), and there was 1 stillbirth (Table 1). In the lat-
ter case, intrauterine fetal demise occurred at 38
weeks of gestation because of carbon monoxide
poisoning in the mother (patient 3). Of the live
births, 20 infants were born before 37 weeks of ges-
tation (Table 4). Of 44 infants, 36 were AGA (appro-
priate for gestational age), 6 were SGA (small for
gestational age), and 2 were LGA (large for gesta-
tional age) (Table 4). These findings in the infants of
women who had been exposed to pharmacologic
doses of prednisone during pregnancy are in con-
trast with those of Reinisch et al [16] who found a
significant decrease in the birth weight of full-term
infants, and a marked increase in the percentage of
newborn infants weighing 2500 g or less." Our find-
ings also are not in keeping with the report that
azathioprine administration in pregnant rats causes
an increased incidence of fetal death as well as fetal
and neonatal growth retardation [17].
Of the 44 live newborns, 31 had an uncomplicated
neonatal course. The remaining 13 newborns had
one or more complications. Four had congenital
anomalies (4b, 8, 13, and 17a), 4 had respiratory dis-
tress syndrome (13a, ISa, 18c and 21), 2 had adre-
nocortical insufficiency (l4a and 17a), 2 had septi-
cemia (2b and 15), and 1 newborn had seizures of
undetermined etiology (11).
Discussion
Because of the uncertain life expectancy follow-
ing renal transplantation, the patients must be coun-
seled in family planning. It must be made clear to
those desiring parenthood that they may not live
long enough to rear their children to adulthood and
may leave their spouses with the problem of raising
their children [6, 7]. This is borne out by the statis-
tics of the Human Renal Transplant Registry [18] in
which there are data on 132 male and female trans-
plant recipients who became parents, and of whom
2 of 64 mothers and 7 of 68 fathers have sub-
sequently died. All patients who have completed
their families or have no desire to have children
should be offered sterilization at the time of trans-
plantation or at some time thereafter, as was done
in a third of our female patients who became preg-
nant. Those wishing to become parents should be
advised to practice contraception for at least 18
months postoperatively. As thromboembolism and
hypertension are common in transplant patients, we
are disinclined to use the oral contraceptive agents
because they may increase the incidence of these
complications. In the normal female population,
there have been reports [19, 20] of serious and even
fatal infections following the insertion of intra-
uterine devices. Theoretically, this complication is
more likely to occur in immunosuppressed renal
transplant patients. This, however, has not been
our experience thus far. Despite this, we recom-
mend less risky forms of contraception such as the
diaphragm, condom, and contraceptive foams and
creams.
In patients with preexisting renal functional im-
pairment, any further deterioration during preg-
nancy is an indication for termination of the gesta-
tion, as was done in 5 patients in our series. If the
pregnancy continues, there is a risk of permanent
impairment of renal function, as occurred in 3 of our
patients. Most recipients with satisfactory pregesta-
tional renal function go through pregnancy and de-
livery without any significant change. Several au-
thors [21—27], however, have described patients in
whom renal functional impairment developed dur-
ing pregnancy and persisted following delivery.
This has also occurred in one of our patients. The
cause of the functional deterioration is not known.
Rudolph, Shweitzer, and Bartus [26] suggested that
rejection might be responsible. Acute rejection
seems unlikely [28]. Pregnancy is regarded as an im-
munologically privileged state, caused by hormonal
and immunologic mechanisms, which protect the
mother from rejecting the fetus and may also pro-
Length of
followup
Patient no. Studiesa Before During After months
la BUN,mg/dl 16 14 24
Ccr,mllmifl 71 86 57
Albuminuria 0 Tr 0
Blood pressure, mm Hg 122/82 140/100 108/80
lb BUN,mg/dI 24 19 23
C, mI/mm 57 78 64
Albuminuria 0 1.3 1 +
Bloodpressure,mmHg 108/80 110/60 110/78
2a BUN ,mg/dI 17 14 18
Ccr,mI/mifl 53 48 37
Albuminuria Tr 1 + I+
Bloodpressure,mm Hg 110/70 130/90 94/60
2b BUN,mg/dI 18 12 21
Ccr,mI/min 37 35 64
Albuminuria 1 + Tr 0
Blood pressure, mm Hg 94/60 120/80 108/80
3 BUN,mg/dl 9 8 16
Ccr,mI/min 112.5 144 117
Alburninuria 0 0 0
Blood pressure, mm Hg 96/70 130/86 110/70
4a BUN,mg/dI 16 13 10
Ccr,mI/min 71 93 89
Albuminuria 0 0 0
Blood pressure, mm Hg 116/62 116/62 90/50
4b BUN,mg/dI 12 9 21 4
Ccr, mi/mm 74 75 86
Albuminuria 0 Tr 0
Bloodpressure,mmHg 102/60 100/50 112/88
5 BUN,mg/dl 15 9 15
Ccr, mi/mm 61 64 67
Albuminuria 0 0 0
Bloodpressure,mmHg 114/68 100/64 104/80
6 BUN,mg/dl 30 15 27
Cer,mi/min 34 — 36
Albuminuria 0 0 0
Blood pressure, mm Hg 154/100 150/110 140/100
7 BUN,mg/dl 27 21 14
Ccr,mI/min 65 65 67
Albuminuria 0 Tr 0
Bloodpressure,mmHg 110/76 106/84 120/90
8 BUN,mg/dI 20 16 17
mI/mm 66 64 65
Albuminuria Tr Tr 0
Blood pressure, mm Hg 122/96 120/70 106/52
9 BUN, mg/di 60 93 37
Ccr, mI/mm 16 14 47
Albuminuria 0 0.87 0
Blood pressure, mm Hg 150/90 158/80 132/68
10 BUN,mg/dl 11 12 15
Ccr,mI/min 111 135 113
Albuminuria Trto 1+ 1+ to2+ 0
Blood pressure, mm Hg 130/90 130/88 118/80
11 BUN,mg/dl 18 20 17
Ccr,mI/min 72 68 78
Albuminuria 2+ 0 0
Blood pressure, mm Hg 140/88 120/80 125/80
12a BUN,mg/dI 15 16 17
Ccr,ml/min 92 102 87
Albuminuna 0.4 0.6 Tr
Blood pressure, mm Hg 134/96 142/108 120/84
12b BUN, mg/di 13 15 12
C,mI/min 93 — 82
Albuminuna 0 — 0
Blood pressure, mm Hg 128/100 142/96 130/90
12c BUN,mg/di 13 17 21
Ccr,mi/min 83 57 75
Albuminuria 0 2+ 0
Blood pressure, mm Hg 124/90 140/100 140/80
57
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Table 3. Laboratory data before, during, and after pregnancy
24
59
49
45
19
93
55
96.5
99
76
94
50 (Died)
138
98
50
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Table 3 (continued)
Length of
followup
Patient no. Studies Before During After months
13 BUN,mg/dI 21 26 23
Ccr,ml/min 69 59 75
Albuminuria 0 1.2 0
Blood pressure, mm Hg 98/68 118/90 126/90
14a BUN,mg/dl 9 9 12
Ccr,m//min 60 71 64
Albuminuria Tr Tr Tr
Blood pressure, mm Hg 116/78 128/80 110/82
14b BUN, mg/d/ 12 10 14
Ccr, mI/mm 64 82 74
Albuminuria Tr Tr 0
Blood pressure, mm Hg 110/82 120/68 100/64
15a BUN,mg/dI 27 26 39
Ccr,mI/min 54 65 53
Albuminuna 0 0 1 +
Bloodpressure, mm Hg 90/70 100/78 102/90
l5b BUN, mg/dI 32 — 39
Ce,., mI/mm 45 — 50
Albuminuria 1 + — —
Bloodpressure,mmHg 100/70 124/100 110/90
15c BUN,mg/dI 28 34 73
Ccr, mI/mm 52 36 30
Albuminuria 3+ 3+ 3+
Blood pressure, mm Hg 100/78 130/92 150/100
16 BUN,mg/dI 39 33
Ccr,mI/min 49 41
Albuminuria 3.2 3.9 No data
Blood pressure, mm Hg 140/100 122/90
17a BUN,mg/dI 24 20 27
Ccr, mI/mm 77 88 72
Albuminuria Tr Tr Tr
Blood pressure, mm Hg 114/80 112/82 98/50
17b BUN, mg/dI 20 16 14
Ccr,mI/min 77 86 77
Albuminuria 0 0 0
Blood pressure, mm Hg 98/50 98/58 90/76
18a BUN, mg/dI 12 15 8
Ccr,m//min 78 85 116
Albuminuria 0 0 0
Blood pressure, mm Hg 110/80 104/82 110/60
18b BUN,mg/dI 9 9 11
Ccr,mI/min 97 114 85
Albuminuria Tr Tr Tr
Blood pressure, mm Hg 104/82 110/78 110/80
18c BUN,mg/dI 11 9 12
C, mI/mm 85 97 83
Albuminuria Tr Tr Tr
Blood pressure, mm Hg 110/80 108/74 100/70
18d BUN, mg/dl 12 8 14
Ccr,m//min 71 76 71
Albuminuria 0 0 Tr
Blood pressure, mm Hg 90/70 90/70 120/85
19 BUN,mg/dl 26 16 11
Ccr,mI/min 109 108 125
Albuminuria 1.4 > 6.0 1.5
Bloodpressure,mmHg 116/92 138/110 122/90
20a BUN,mg/dI 14 14 13.5
Ccr,ml/min 138 117 111
Albuminuria 1+ 2+ Tr
Blood pressure, mm Hg 114/74 144/90 128/88
20b BUN,mg/dI 13.5 11 7.5
Ccr,ml/min 111 62 73
Albuminuria Tr Tr Tr
Blood pressure, mm Hg 128/88 150/100 114/74
21 BUN,mg/dI 44 37 51
mi/mm 24 25 20
Albuminuria 1.4 10.8 2.4
Blood pressure, mm Hg 110/78 140/90 130/82
66
141
105
37
25.5
9 (Died)
30 (Died)
99
82 (Died)
136
130
117
100
104
67.5
49
129
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Table 3 (continued)
Length of
followup
Patient no. Studies Before During After months
22 BUN,mg/dl 16 11 8
Ccr,ml/min 103 120 106
Albuminuria 0 Tr 0
Blood pressure, mm Hg 100/80 115/70 —
23 BUN,mg/d/ 14 11 16 48
Ccr, mI/mm 77 79 83
Albuminuria 0 2+ 0
Blood pressure, tom Hg 114/86 114/72 110/70
24 BUN,mg/dI 26 15 27 45
Ccr,mI/min 66 60 120
Albuminuria 0 0.6 0
Blood pressure, mm Hg 114/84 112/90 124/84
25a BUN,mg/dl 20 13 21 41
Ccr, mI/mm 54 64 26
Albuminuria 0 0 2+
Blood pressure, mm Hg 124/88 130/104 132/104
25b BUN,mg/dl 14 14 6
Ccr,mI/min 46 70 No
Albuminuria 2+ 2+ data
Blood pressure, mm Hg 130/78 114/96
26 BUN,mg/dI 20 34 Still
Ccr,mI/min 62 68 pregnant
Albuminuria 1+ 7.6
Blood pressure,mm Hg 140/110 160/130
27 BUN,mg/dI 10 14 8 34
Ccr, mI/mm 53 56 47
Albuminuria 0 + 0
Blood pressure, mm Hg 88/70 94/70 90/60
28 BUN,mg/dI 8 7 7 17
Ccr,mI/min 186 126 69
Albuminuria 3.4 1.9
Bloodpressure,mmHg 130/94 134/102 126/100
29 BUN, mg/dI 30 32 Still
Ccr,ml/min 39 50 pregnant
Albuminuria Tr Tr
Blood pressure, mm Hg 120/80 120/80
30 BUN, mg/dI 20 21 38 54
Ccr,mI/min 51 62 37
Albuminuria 0 0 0.5
Blood pressure, mm Hg 110/80 120/80 114/84
31a BUN,mg/dl 8 12 22 66
Car, mI/mm 80 80 70
Albuminuna 0 + 0
Blood pressure, mm Hg 100/68 130/94 130/94
31b BUN,mg/dl 12 8 11 49
Ccr,mI/min 81 80 97
Albuminuria Tr+ 0 0
Blood pressure, mm Hg 130/94 100/68 98/54
31c BUN,mg/dI 11 9 — 20
Ccr,mI/min 97 97 —
Albuminuria 0 0 —
Blood pressure, mm Hg 98/54 112/88 100/70
32 BUN,mg/dI 11 24 36 17
Ccr, mI/mm 79 44 —
Albuminuria 0 Tr 0
Blood pressure, mm Hg 98/68 108/70 110/70
33 BUN,mg/dl 42 21 33 4
Cr,mi/mm 57 88 43
Albuminuria 2+ 2.2 6.4
Blood pressure, mm Hg 112/86 170/110 126/96
34a BUN,mg/dI 21 17 19 36
Ccr,mI/min 57 85 68
Albuminuria 0 0.7 0
Blood pressure, mm Hg 120/90 122/84 120/110
34b BUN,mg/dI 18 13 20 10
Ccr, mI/mm 65 49 80
Albuminuna 0 0 0
Blood pressure,mm Hg 118/90 122/74 112/76
49
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Table 3. Laboratory data before, dun ng, and after pregnancy (continued)
Length of
foHowup
Patient no. Studiesa Before During After months
35 BUN,mg/dI
Cc,m1/min
Albuminuria
Blood pressure, mm Hg
13
74
0
98/72
12
97
0
130/70
Still
pregnant
—
36a BUN,mg/dl
Ccr, mI/mm
Albuminuria
Blood pressure, mm Hg
26
54
0
108/64
31
63
2+
138/78
37
54
0
130/70
19
36b BUN,mg/dI
Ccr, mI/mm
Albuminuria
Blood pressure,mm Hg
37
54
0
130/70
45
44
0
108/60
30
25
1 +
110/80
12
37a
37b
BUN, mg/d/
Ccr,m1/min
Albuminuna
Blood pressure, mm Hg
BUN,mg/dl
Ccr,ml/min
Albuminuria
Blood pressure,mm Hg
24
62
Tr
100/70
13
105
—
100/50
—
101
+
120/90
12
82
0
128/92
13
105
—
100/50
11
79
0
100/60
39
24
a The BUN and creatinine clearance figures are average values for 6 months before, during, and after pregnancy. The albuminuria and
blood pressure figures are maximum values for respective intervals. Albuminuna status is denoted as follows: 0, Tr (trace), and specific
values, which are in grams per day.
tect the renal homograft [28, 29]. In fact, some
women have had substantial reductions or even ces-
sation of immunosuppressive therapy during preg-
nancy without deterioration of renal function [28].
Although acute rejection may not be a problem, the
process of chronic rejection may continue during
pregnancy. In interpreting the results of renal func-
tion studies in pregnant transplant patients, Rifle
and Traeger [28] mention that proteinuria frequent-
ly increases during the third trimester, but that this
elevation has no negative significance, and that
there is a transitory decrease in GFR near term.
Theoretically, the termination of pregnancy and
its naturally immunosuppressed state should be fol-
lowed by an increased risk of rejection. Several au-
thors have occasionally augmented the dose of cor-
ticosteroids during or following delivery, for peri-
ods of 5 days to 3 months after termination of
pregnancy [28]. Apart from 100-mg doses of hydro-
cortisone every 8 hours to protect the patient from
the stress of labor, we have not found that increased
dosage of corticosteroid therapy was necessary [6].
In our series, 27% of the patients developed tox-
emia, which is approximately a fourfold increase in
the incidence in the nontransplant pregnant popu-
lation. Of the 15 patients, 10 developed pre-
eclampsia superimposed on preexisting hyper-
tension and/or renal impairment, and in the remain-
ing 5 recipients this occurred de novo. Three of
these patients developed persistent impairment of
renal function. None developed eclampsia, but Wil-
liams and Jelen [30] report the rapid development of
eclampsia and abortion in a patient who had had a
renal transplant.
Although some authors have described an in-
creased incidence of infections in transplant pa-
tients during pregnancy [26], this has not been our
experience. Patients should be carefully monitored,
however, for this possibility, particularly with re-
gard to urinary tract infections.
The transplanted kidney does not cause mechani-
cal dystocia during labor, as it is usually situated in
the false pelvis. The renal homograft blood vessels
and ureter may be subjected to compression during
labor, but we have not observed any harmful con-
sequences as a result of this. If there is any question
of homograft compression or of obstruction of labor
by the transplanted kidney, some workers [28-3 1]
recommend simultaneous intravenous pyelography
and X-ray pelvimetry.
An increased incidence of malignancy has been
observed in renal transplant recipients [32, 33].
There is a 13-fold increase in the incidence of
squamous-cell carcinoma of the cervix in renal
homograft recipients, including I patient in the
present series (patient 17) [4, 33, 34]. Another pa-
tient (patient 10) had an adenocarcinoma of the en-
dometrium. This experience emphasizes the need
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Table 4. Data on newborns of female kidney recipient
Gestational Birth-
Patient age weight Classifi-
no. Sex weeks gm cationa Neonatal problems
Normalla F 41 2790 AGA
lb F 39 2870 AGA Normal
2a M 33 2351 AGA Normal
2b M 36 2081 AGA DiedofsepsisatlOdays
3 M 38 2470 AGA Intrauterine death secondary to carbon monoxide poisoning in the
mother
4b F 41 2385 SQA Respiratory problems, deformed left hand
7 F 36 1826 SGA Normal
8 F 33 1600 AGA Probable peripheral pulmonary arterial stenosis (mild).
Intraarticular benign hemangioma excised from left knee at 3V2
years
10 F 37 2820 AGA Normal
11 M 40 2888 AGA Seizures of unknown etiology, controlled with phenobarbitol
12a F 41 3500 AGA Normal
12b M 40 3850 LGA Normal
12c M 42 3171 AGA Normal
13 M 32 1340 SGA Mild respiratory distress syndrome; operation for bilateral inguinal
hernia at 4 months
14a F 27 2100 SGA Adrenocortical insufficiency, lymphopenia, shock, recovered
14b F 36.5 2378 AGA Normal
iSa M 35 2780 AGA Mild respiratory distress syndrome. Septicemia with group D
Streptococcus
15c F 36 2640 AGA Normal
l7a M 39 2869 AGA Adrenocortical insufficiency, lymphopenia; recovered. Congenital
pulmonary artery stenosis, surgically corrected at 4 months
17b M 40 3044 AGA Normal
18b M 33 1920 AGA Normal
l8c M 34 1910 AGA Respiratory distress syndrome and pneumonia; recovered
18d F 40 2294 SGA Normal
20a M 40 2690 AGA Cesarean section for fetal distress caused by cord entanglement.
Child normal after delivery
20b F 40 3398 AGA Normal
21 F 29 1040 AGA Respiratory distress syndrome; died at 8 hours
22 M 36 2955 AGA Normal
23 M 40 3427 AGA Respiratory problems, hyperbilirubinemia
24 F 37 2984 AGA Normal
25a M 40 3597 AGA Normal
25b
25b
M
M Twins
28.5
28.5
1127
1269
AGA
AGA
Normal
Normal
27 M 36 2225 AGA Normal
28 F 40 2749 AGA Normal
30 M 36 2541 SGA Normal
3 la F 40 2840 AGA Normal
31b F 41 3285 AGA Normal
31c M 37 3009 AGA Normal
32 M 40 2898 AGA Normal
33 F 36 1970 AGA Normal
34a M 38 3597 LGA Hyperviscosity
34b M 36 3069 AGA Mild respiratory problems. Hyperviscosity. Slow with development
36a M 36 3125 AGA Normal
37a M 37 2300 AGA Normal
37b M 36 1956 AGA Normal
a Abbreviations are: AGA, appropriate for gestational age, between 10th and 90th percentile in birthweight for a given gestational age;
SGA, small for gestational age, below 10th percentile in birth weight for a given gestational age; LGA, large for gestational age, above
90th percentile in birth weight for a given gestational age.
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for female renal homograft patients to have periodic
pelvic examinations and vaginal cytology.
Whereas the risks to the mother are relatively
low, the risks to the fetus are high. Prematurity oc-
curred in 20(45%). Of the 44 live newborns, 31 were
normal (70%). The remaining 13 (30%) had one or
more complications. Respiratory distress syndrome
occurred in 4 (9%), congenital anomalies in 4 (9%),
adrenocortical insufficiency in 2 (5%), septicemia in
2 (5%), hyperviscosity in 2 (5%), and seizures in 1
(3%).
Premature labor is quite common in nontrans-
plantation patients with poor renal function. Some
of the premature deliveries in the present series
may have resulted from this cause [35], but in the
remaining cases there is no obvious explanation for
the onset of premature labor. One of the complica-
tions of prematurity is the respiratory-distress syn-
drome. There have been recommendations made
that steroid therapy to the mother may prevent the
development of this disorder in the premature infant
[36]. Despite the fact that the mothers in this series
were receiving corticosteroid therapy, four pre-
mature infants did develop the respiratory-distress
syndrome.
It is well recognized that patients with severe re-
nal impairment or with vascular disease can pro-
duce fetuses small for gestational age (SGA) [37]. In
our series, however, only 1 newborn (case 13) of 16
patients with toxemia was small for gestational age.
Another potential risk to the fetus is congenital
defects caused by the immunosuppressive agents.
Based on animal experiments both of the commonly
used agents, azathioprine [38, 39] and the cortico-
steroids [40], have been implicated. Studies in fe-
male mice during early pregnancy showed a high in-
cidence of skeletal and central nervous system
anomalies when the animals were given large doses
of azathioprine (4 to 30 mg/kg body wt). As this
agent causes chromosome aberrations, it is theoret-
ically possible that sperm could be affected, and the
offspring of male patients under treatment could al-
so develop fetal abnormalities. In the present se-
ries, 2 of the offspring of male patients and 4 of the
offspring of female patients had congenital abnor-
malities. Whether these anomalies were related to
the immunosuppressive agents given to the parents
or were purely coincidental is subject to debate. If
we combine these figures with those from other se-
ries [26—28, 41], however, it appears that the in-
cidence of congenital anomalies is small.
Another complication, to which the immuno-
suppressive agents contributed, was encountered in
two newborns who presented with evidence of lym-
phopenia and adrenocortical insufficiency with the
risk of overwhelming infection. This problem
should be suspected whenever a newborn shows
signs of peripheral vascular collapse, such as lethar-
gy, mottled skin, and hypotension. At the time of
birth, a sample of umbilical cord blood should be
examined for serum electrolytes, and a complete
blood count should be done to determine the abso-
lute number of lymphocytes. In suspected cases, an
X-ray of the chest may show an absence of the
thymic shadow, suggesting a state analogous to
congenital thymic aplasia. Once the diagnosis is en-
tertained, the proper therapy consists of hydro-
cortisone, appropriate electrolyte solutions, antibi-
otics, and gamma globulin. In both of our cases,
prompt treatment was life saving, and the syndrome
regressed within a few days.
Newborns of immunosuppressed mothers are
prone to develop infection within the first 8 days of
life. Two premature infants in the present series de-
veloped septicemia, one with Escherichia coil and
the other with group D streptococcus. The latter pa-
tient developed this complication while on therapy
for respiratory distress syndrome, and the other had
an apparently smooth neonatal course until sepsis
developed. Both were treated with the appropriate
antibiotics. The newborn with E. co/i sepsis failed
to respond, however, even when steroid therapy
was added, and died at 10 days of age.
The possibility of fertility problems affecting the
female offspring of female transplant patients has
been raised by Reimers and Sluss [42]. In the hu-
man body, azathioprine is metabolized largely to 6-
mercaptopurine. These workers gave female mice
low doses of 6-mercaptopurine during pregnancy.
Of the surviving female offspring, despite normal
body weight and general appearance, many were ei-
ther sterile or, if they became pregnant, had smaller
litters and more dead fetuses as compared to off-
spring of mothers that had not received the drug.
Only prolonged followup of the offspring of trans-
plant patients will provide an answer as to whether
similar problems may occur in humans.
Chromosome aberrations have been described in
the lymphocytes of several infants born to renal
transplant mothers [43, 44]. Although these dis-
appeared within 32 months, there are two possible
problems. Abnormalities may have persisted in tis-
sues not studied, including the primordial ova, and
these may give rise to abnormalities in the next gen-
eration. Another possible problem is that chromo-
some abnormalities may precede the development
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of malignancies in the affected offspring. Thus far,
none has been reported.
Summary. Following renal transplantation, it is
often possible to achieve parenthood. In female pa-
tients, there are definite risks to both mother and
fetus. For this reason, transplant recipients must be
counseled with regard to family planning, and the
option of sterilization should be offered if so de-
sired. If a female recipient becomes pregnant, she
must be monitored as a high-risk patient. A patient
who has compromised renal function prior to con-
ception and has further deterioration during preg-
nancy should be considered for termination of the
gestation. If the pregnancy continues, there is a risk
of permanent impairment of renal function. In pa-
tients with satisfactory renal function before preg-
nancy, there may be some deterioration of function
during gestation. Usually, this is transient and re-
turns to preexisting levels in the postpartum period.
Renal transplant patients have a 27% risk of devel-
oping preeclampsia during pregnancy. Usually, the
transplanted kidney does not produce any mechani-
cal dystocia during labor. During vaginal delivery,
there is no apparent mechanical injury to the trans-
planted kidney. Because there is a 13-fold increase
in the development of carcinoma of the cervix in
female transplant recipients, it is essential that
these patients have a pelvic examination and vagi-
nal cytology prior to transplantation and period-
ically thereafter.
The risk to the offspring of male transplant recipi-
ents is small. There is a substantial hazard to the
newborn of female recipients; however, forty-five
percent of the newborns were delivered prior to 37
weeks of gestation. Nearly one third had one or
more complications during the neonatal period.
These included respiratory distress syndrome, con-
genital anomalies, lymphopenia and adrenocortical
insufficiency, infection, hyperviscosity, and sei-
zures.
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